Biosite Should Enroll Elderly With Concomitant Illness In CHF Studies - Panel
This article was originally published in The Gray Sheet
Executive Summary
Biosite Diagnostics should enroll elderly people who may have various types of coronary disease or renal insufficiency in order to validate claims that the Triage B-Type Natriuretic Peptide (BNP) point-of-care test effectively diagnoses congestive heart failure (CHF) in at-risk populations, FDA's Clinical Chemistry and Clinical Toxicology Devices Panel recommended March 24 in Rockville, Maryland.